drugset
drugset / Trial / NCT04934891

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547

NCT04934891 ↗

Phase 1 Completed 48 enrolled Ionis Pharmaceuticals, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of the antisense inhibitor ION547 administered subcutaneously (SC) in healthy participants.

Timeline

Start
2021-03-24
Primary completion
2022-09-14
Completion
2022-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject ION547 Antisense oligonucleotide — Subcutaneous

Indications

No indication recorded.